Trending Up0.0200 (1.8519%)
  • Bid / Lots
    1.0900/ 14
  • Ask / Lots
    1.1100/ 1
  • Open / Previous Close
    1.1200 / 1.0800
  • Day Range
    Low 1.0900
    High 1.1600
  • 52 Week Range
    Low 0.5500
    High 5.4500
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 1.08
09:32 ET17611.1241
09:36 ET3291.15
09:41 ET4141.16
09:48 ET1001.1541
09:59 ET2001.14
10:01 ET1001.1388
10:10 ET30001.1385
10:30 ET2001.12
10:39 ET2501.1
10:57 ET4501.1198
11:04 ET1001.11
11:13 ET1001.12
11:20 ET47001.1199
11:51 ET50001.1299
12:12 ET44251.1298
12:20 ET10001.1
12:21 ET10001.1299
12:25 ET20101.1
12:34 ET8001.099
12:45 ET65001.0999
12:48 ET52001.1
01:24 ET3441.1
01:37 ET2001.09
01:48 ET1001.09
01:55 ET3501.09
02:08 ET2001.09
02:15 ET1001.1
02:18 ET4001.1
02:20 ET1001.1
02:26 ET2001.1
02:33 ET2001.1
02:36 ET1001.1
02:47 ET1001.1
02:56 ET2001.1
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesADXN
Addex Therapeutics Ltd
United StatesAGE
AgeX Therapeutics Inc
United StatesMTCR
Metacrine Inc
United StatesINTI
Inhibitor Therapeutics Inc
United StatesTFFP
TFF Pharmaceuticals Inc
United StatesEVLO
Evelo Biosciences Inc
As of 2023-03-28

Company Information

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Contact Information

Chemin des Mines, 9PLAN-LES-OUATES, Switzerland 1202


Independent Non-Executive Chairman of the Board of Directors
Vincent Lawton
Chief Executive Officer, Member of the Executive Management, Member of the Board of Directors
Tim Dyer
Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
Roger Mills
Member of the Executive Management, Head of Translational Science
Mikhail Kalinichev
Member of the Executive Management, Head of Discovery - Biology
Robert Lutjens

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.